Bright Minds Corp (DRUG) - Long-Term Debt to Capital Coefficient

Bright Minds Corp - graphic logo of issuer DRUG

Bright Minds Biosciences (DRUG) is developing modified psychedelics to combat depression, eliminating hallucinogenic side effects through precise chemical tuning. The business relies on global logistics for rare components, which mitigates regulatory risks and maintains high profitability. This price chart on GURU.Markets, where the metric stands at 0.00, illustrates the trading dynamics and complements data on the implementation of robots for accelerated molecular analysis of new compounds.

Bright Minds Bio (DRUG): Long-Term Debt to Equity from 07/04/2022 to 10/31/2026

Comprehensive metric breakdowns and analytics for Bright Minds Biosciences (DRUG)

- stock price and consensus target price:
Quote Chart Bright Minds Bio|DRUG - Analyst Consensus Forecast
- market capitalization indicators:
Market Value Bright Minds Biosciences Inc.|DRUG - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Bright Minds Biosciences|DRUG - Company Book Value|Market Value to Book Value brightmindsbio.com|DRUG - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Bright Minds Biosciences|DRUG - Long-Term Debt to Capital|Short-Term Debt to Capital brightmindsbio.com|DRUG - Company Total Debt|Debt to Net Assets Ratio Bright Minds Biosciences Inc.|DRUG - Company Long-Term Debt|Current Liabilities Bright Minds Biosciences|Interim Coverage Ratio brightmindsbio.com
- net income and valuation ratios data:
DRUG - Net Income
General company analysis:Bright Minds Bio - DRUG
Signature product of Bright Minds Biosciences

This ratio determines the issuer's financial autonomy by measuring long-term liabilities relative to equity to assess resilience against rising interest rates. By analyzing the ratio of long-term loans to equity, an investor can evaluate the liquidity shortage risk for Bright Minds Biosciences (DRUG) amid a lack of revenue and highly speculative expectations regarding upcoming clinical trials.

Analysis of competing companies

Alkermes PLC - Long-Term Liabilities to Equity|Long-Term Debt to Capital AVDL|ATAI (atai) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital GHRS (GH Research PLC)|Long-Term Debt to Capital mindmed.co MNMD|CMPS - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient LBRX (LB Pharmaceuticals, Inc.)|Vanda Pharmaceuticals Inc (VNDA) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Cybin|ANRO (Alto Neuroscience, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Capital nrxpharma.com|Long-Term Debt to Equity Ratio CING (Cingulate Inc.)|SILO (silopharma.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity China Pharma Holdings, Inc. CPHI|CMND (Clearmind Medicine, Inc.) - Long-Term Liabilities to Equity|PBM - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital scisparc.com SPRC|SEEL (Seelos Therapeutics, Inc.) - Long-Term Debt to Equity Ratio|Long-Term Liabilities to Capital Virpax Pharmaceuticals, Inc. (VRPX)|KRTX (Karuna) - Long-Term Debt to Capital